A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589

Phase 1

Completed

• Conditions: Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies
• Interventions: Drug: LBH589

• Registration Number: NCT00472368
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This single center study will help determine the absorption, metabolism, and excretion of LBH589 and to assess the safety and efficacy of LBH589 in advanced cancer patients for whom no standard therapy exists.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-05
• Study First Submitted: 2007-05-10
• Study First Submitted QC: 2007-05-10
• Study First Posted: 2007-05-11
• Primary Completion: 2008-06
• Status Verified: 2012-04
• Last Update Submitted: 2012-04-27
• Last Update Posted: 2012-05-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
LBH589	LBH589	-

Primary Outcome Measures

Name	Time	Method
Rates and routes of excretion of LBH589 and its metabolites in urine and feces following administration of a single oral dose of [14C] LBH589	during the first 8 days on study	oral dose of \[14C\] LBH589

Secondary Outcome Measures

Name	Time	Method
Safety Efficacy

Trial Locations

Locations (1)

Novartis Investigative Site; 🇺🇸 Buffalo, New York, United States